CV Lattes
ORCID
Google Scholar Citations
Sociedade Beneficente de Senhoras (SBSHSL). Hospital Sírio-Libanês (Institutional affiliation from the last research proposal) Birthplace: Brazil
Érico Tosoni Costa holds a BSc in Biological Sciences from the University of São Paulo (USP, 2000), a PhD in Biochemistry and Molecular Biology from the Institute of Chemistry at USP (2005), and a Postdoctoral degree in Molecular Biology and Cancer Genetics from the Ludwig Institute for Cancer Research (ILPC) at AC Camargo Hospital (2006-2009). From 2009 to 2016, he served as an Assistant Researcher in the Molecular Biology and Genomics group at ILPC. In 2011, he was a visiting researcher at the Ludwig Institute for Cancer Research at the University of California, San Diego (UCSD). He is currently a Senior Researcher at the Teaching and Research Institute of Sírio-Libanês Hospital (IEP-HSL), where he is part of the Molecular Oncology Center (MOC) and teaches Tumor Biology to graduate students. His recent research spans from basic studies on 3D cultures of tumor cells to the development of patient-derived organoids (PDOs) and pre-clinical screening using in vitro PDO models, with a focus on advancing the personalization of cancer treatment. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Breast cancers (BC) currently have a cure rate of more than 80%, but remain the most frequent and deadly neoplasm in the female population, with more than 2 million cases and 685,000 deaths occurring globally each year. Its treatment includes both locoregional and systemic therapy approaches. With classification refinement, systemic strategies differ according to molecular subtype, includ…
Diffuse gliomas are the most common malignant primary brain tumors of adults and are highly therapy resistant. The most frequent and highly lethal variants are referred to as glioblastoma (GBM), which have a highly invasive and aggressive nature, making this class hardly treatable. Neurosurgical cure is an unattainable goal for GBM and, unfortunately, GBM continues to be uniformly fatal, …
Natural products are a valuable matrix of compounds with many applications in various areas of Pharmacology, Biology, and Medicine. This is particularly evident in the field of modern oncology, where more than three-quarters of all anticancer compounds are derived from these products, either by structural modification of the original natural compounds (semisynthesis) or by the integral sy…
Astrocytomas are aggressive tumors from the central nervous system (CNS) developing from astrocytes. The most common and fatal subtype is the Glioblastoma Multiforme (GBM, grade IV, WHO). High-grade astrocytomas (grades III and IV) exhibit a so-called "infiltrative growth" pattern of brain spreading, which emerges as a combination of uncontrolled cell proliferation and intense parenchymal…
Glioblastoma Multiform (GBM) is the most common and lethal human intracranial malignancy. Due to the high rate of recurrence, the bad prognosis and inefficiency of existing therapies, there is the need for better understanding control mechanisms of invasion in GBM for the development of interventions that inhibit the progression of this cancer. ADAM family consists of a group of desintegr…
Widespread brain infiltration is a hallmark of malignant brain tumors. Particularly in the case of glioblastomas (GBM) - the most common and aggressive type of brain tumors in adults -, despite maximal initial tumor resection and multimodality therapy, 90% of GBM patients will experience disease recurrence within few years of treatment, mainly due to their aggressive invasiveness into the…
Malignant phenotype evolves through a fine-tuning of certain inherent molecular programs. Within this context, epigenetic silencing of ADAM23 gene arises as a recurrent event in a wide range of tumors, frequently associated with metastatic disease and/or tumor progression. We show that ADAM23 expression is gradually downregulated during glioma progression compared to normal brain samples,…
| 1 / 1 | Ongoing grants |
| 2 / 1 | Completed research grants |
| 8 / 3 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 13 / 7 | All research grants and scholarships |
| Associated processes | |